KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.96

Clinical outcomes by type of surgery with perioperative durvalumab in patients with resectable non-small cell lung cancer.

David Harpole, John V Heymach, Martin Reck, Janis Taube, Shugeng Gao, Gaofeng Li, Jian You, Dinh Van Luong, Somcharoen Saeteng, Ruth Doake, Tamer M Fouad, Tetsuya Mitsudomi

J Thorac Cardiovasc Surg S0022-5223(26)01288-2

PMID42692248
PMCID-
DOI10.1016/j.jtcvs.2026.04.058
发表日期2026-09-03
入排依据:明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
摘要

摘要

OBJECTIVE: To assess outcomes with perioperative durvalumab by type of surgery in patients with resectable non-small cell lung cancer (NSCLC) from the AEGEAN study. METHODS: AEGEAN is a double-blind, placebo-controlled phase 3 study (NCT03800134) of adults with treatment-naïve, resectable NSCLC (stage II-IIIB [N2]) who were randomized 1:1 to neoadjuvant chemotherapy plus durvalumab or placebo before surgery followed by adjuvant durvalumab or placebo. Primary end points were pathologic complete response and event-free survival in the modified intent-to-treat population, which excluded patients with documented EGFR/ALK aberrations. RESULTS: Of 295 and 302 patients in the durvalumab and placebo arms, respectively, who underwent surgery (modified intent-to-treat population), 80.7% versus 73.2% had lobectomy, 7.5% versus 12.3% had sleeve resection/bilobectomy, and 9.2% versus 9.6% had pneumonectomy. Rates of pathologic complete response were greater in the durvalumab versus placebo arm, regardless of surgery type (lobectomy: 21.0% vs 5.4%; sleeve resection/bilobectomy: 36.4% vs 5.4%; and pneumonectomy: 7.4% vs 3.4%). Event-free survival benefit favored the durvalumab versus placebo arm, regardless of surgery type (lobectomy: hazard ratio [HR], 0.64; 95% CI, 0.46-0.88; sleeve resection/bilobectomy: HR, 0.59; 95% CI, 0.22-1.40; and pneumonectomy: HR, 0.80; 95% CI, 0.36-1.74). The rates of maximum grade ≥3 surgical complications were low across both arms, regardless of surgery type (lobectomy: 4.2% vs 9.5%; sleeve resection/bilobectomy: 13.6% vs 5.4%; and pneumonectomy: 14.8% vs 6.9%). CONCLUSIONS: Clinical benefit with perioperative durvalumab plus neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone was generally maintained across the surgery subgroups.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。